Edgewise Therapeutics, Inc. (EWTX)
EWTX moved a median of +0.11% 30 minutes after news, and +0.38% by the close. How EWTX actually reacts to news — the realized, point-in-time move the market made, measured across 378 labeled events over the last three years with zero look-ahead.
EWTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.17% | 55% | 377 |
| 30-min | +0.11% | 52% | 377 |
| 60-min | -0.21% | 42% | 377 |
| to close | +0.38% | 55% | 373 |
| Middle 50% of EWTX reactions | -1.09% to +1.15% |
|---|---|
| Median reaction (30-min) | +0.11% |
| Measured reactions | 378 |
Half of all Edgewise Therapeutics, Inc. news events land between -1.09% and +1.15% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How EWTX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 24 | -0.26% | 42% | -0.06% |
| Rating reiterations | 67 | +0.08% | 55% | -0.75% |
| Price-target raises | 14 | +0.25% | 86% | -0.68% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how EWTX ranks against every other measured name →
That’s how EWTX usually reacts — get an email when it moves on news →Email me when EWTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to EWTX's baseline. Nothing else.
Recent EWTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400 | Press release | PR Newswire | +1.19% | +2.86% | |
| Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | Press release | PR Newswire | +1.26% | +0.22% | |
| Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500 | Press release | PR Newswire | -1.18% | -1.07% | |
| Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | Press release | PR Newswire | +2.39% | -1.48% | |
| Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 | Press release | PR Newswire | -0.07% | +2.40% | |
| Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | Press release | PR Newswire | +0.79% | +0.66% | |
| Form 10-Q Edgewise Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.79% | +0.66% | |
| Form 8-K Edgewise Therapeutics, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.79% | +0.66% | |
| Form 8-K/A Edgewise Therapeutics, For: Jul 10 | SEC filing · Form 8-K | SEC EDGAR | -1.18% | -5.82% | |
| Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline | Press release | PR Newswire | -2.77% | -6.90% | |
| Form 8-K Edgewise Therapeutics, For: Jul 10 | SEC filing · Form 8-K | SEC EDGAR | -2.77% | -6.90% | |
| Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Press release | PR Newswire | -2.77% | -6.90% | |
| Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | Press release | PR Newswire | +3.35% | -2.90% | |
| Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) | Press release | PR Newswire | -5.94% | -5.69% | |
| Form 8-K Edgewise Therapeutics, For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | +2.41% | -1.86% | |
| Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | Press release | PR Newswire | +1.14% | +3.44% | |
| Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline | Press release | PR Newswire | -3.83% | -0.84% | |
| Form 8-K Edgewise Therapeutics, For: May 31 | SEC filing · Form 8-K | SEC EDGAR | -3.83% | -0.84% | |
| Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Press release | PR Newswire | -3.83% | -0.84% | |
| Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026 | Press release | PR Newswire | -2.03% | -1.56% | |
| Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications | Press release | PR Newswire | -3.97% | -6.37% | |
| Form 10-Q Edgewise Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.97% | -6.37% | |
| Form 8-K Edgewise Therapeutics, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -3.97% | -6.37% | |
| Form S-8 Edgewise Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.22% | -0.09% | |
| Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | Press release | PR Newswire | +0.67% | +3.08% | |
| Form ARS Edgewise Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.03% | +0.57% | |
| Form DEF 14A Edgewise Therapeutics, For: Jun 04 | SEC filing · Form DEF | SEC EDGAR | -1.03% | +0.57% | |
| Form DEFA14A Edgewise Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -1.03% | +0.57% | |
| Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | Press release | PR Newswire | +1.95% | +3.56% | |
| Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up | Press release | PR Newswire | +0.73% | +2.23% | |
| Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026 | Press release | PR Newswire | -1.25% | -3.51% | |
| Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference | Press release | PR Newswire | -1.50% | -1.67% | |
| Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | Press release | PR Newswire | +0.55% | -0.80% | |
| Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs | Press release | PR Newswire | -1.57% | -0.80% | |
| Form 10-K Edgewise Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.57% | -0.80% | |
| Form 8-K Edgewise Therapeutics, For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -1.57% | -0.80% | |
| Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 | Press release | PR Newswire | +0.00% | -3.58% | |
| Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | Press release | PR Newswire | +1.10% | +2.63% | |
| Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 | Press release | PR Newswire | -0.21% | +2.93% | |
| Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 | Press release | PR Newswire | +0.94% | -1.97% | |
| Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | Press release | PR Newswire | -0.76% | -0.30% | |
| Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy | Press release | PR Newswire | +7.52% | +21.50% | |
| Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | Press release | PR Newswire | +1.41% | -9.06% | |
| Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors | Press release | PR Newswire | +1.10% | -2.41% | |
| Form 8-K Edgewise Therapeutics, For: Nov 19 | SEC filing · Form 8-K | SEC EDGAR | -2.16% | +2.12% | |
| Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | Press release | PR Newswire | -2.82% | -1.21% | |
| Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers | Press release | PR Newswire | +0.82% | +6.65% | |
| Form 8-K Edgewise Therapeutics, For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +0.44% | +17.50% | |
| Edgewise Therapeutics to Participate in Upcoming Investor Conferences | Press release | PR Newswire | +0.70% | +0.65% | |
| Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Press release | PR Newswire | -0.17% | -2.84% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the EWTX section they belong to.
Where else EWTX is measured.
EWTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Edgewise Therapeutics, Inc.'s median reaction calculated?
Every labeled EWTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 378 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of EWTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does EWTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.